- Home
- NSPR vs DBVT Comparison
NSPR vs DBVT Comparison
Compare NSPR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- DBVT
- Stock Information
- Founded
- NSPR 2005
- DBVT 2002
- Country
- NSPR United States
- DBVT France
- Employees
- NSPR N/A
- DBVT N/A
- Industry
- NSPR Medical/Dental Instruments
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NSPR Health Care
- DBVT Health Care
- Exchange
- NSPR Nasdaq
- DBVT Nasdaq
- Market Cap
- NSPR 99.7M
- DBVT 464.0M
- IPO Year
- NSPR N/A
- DBVT N/A
- Fundamental
- Price
- NSPR $2.13
- DBVT $15.52
- Analyst Decision
- NSPR Strong Buy
- DBVT Buy
- Analyst Count
- NSPR 2
- DBVT 5
- Target Price
- NSPR $4.50
- DBVT $15.85
- AVG Volume (30 Days)
- NSPR 67.6K
- DBVT 195.2K
- Earning Date
- NSPR 11-04-2025
- DBVT 10-28-2025
- Dividend Yield
- NSPR N/A
- DBVT N/A
- EPS Growth
- NSPR N/A
- DBVT N/A
- EPS
- NSPR N/A
- DBVT N/A
- Revenue
- NSPR $7,066,000.00
- DBVT $5,502,000.00
- Revenue This Year
- NSPR $7.48
- DBVT $1,743.46
- Revenue Next Year
- NSPR $104.39
- DBVT $1,044.34
- P/E Ratio
- NSPR N/A
- DBVT N/A
- Revenue Growth
- NSPR 7.60
- DBVT N/A
- 52 Week Low
- NSPR $1.99
- DBVT $2.21
- 52 Week High
- NSPR $3.80
- DBVT $18.00
- Technical
- Relative Strength Index (RSI)
- NSPR 24.89
- DBVT 57.73
- Support Level
- NSPR $2.21
- DBVT $13.89
- Resistance Level
- NSPR $2.41
- DBVT $16.95
- Average True Range (ATR)
- NSPR 0.09
- DBVT 1.02
- MACD
- NSPR -0.02
- DBVT -0.30
- Stochastic Oscillator
- NSPR 1.28
- DBVT 40.65
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.